Management of breakthrough seizures in the emergency department: Continuity of patient care

Current Medical Research and Opinion

Volumn 23, Issue 7, 2007, Pages 1583-1592

  Montouris, Georgia D ^a,b   Jagoda, Andy S ^c,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Anticonvulsants; Continuity of patient care; Emergency service; Epilepsy; Hospital; Referral and consultation

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ABDOMINAL PAIN; ABNORMAL VISION; ACCIDENTAL INJURY; AGITATION; ANHIDROSIS; ANOREXIA; ANXIETY; APLASTIC ANEMIA; ARTHRITIS; ASTHENIA; ATAXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BLURRED VISION; BRONCHITIS; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONFUSION; CONSULTATION; COORDINATION DISORDER; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; DYSMENORRHEA; DYSPEPSIA; EDEMA; EMERGENCY WARD; EPILEPTIC STATE; EYE DISEASE; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; GAIT DISORDER; HEADACHE; HEALTH CARE PERSONNEL; HOSTILITY; HUMAN; HYPERPYREXIA; HYPERSENSITIVITY; HYPONATREMIA; INFECTION; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LANGUAGE DISABILITY; LIVER FAILURE; MEDICAL DECISION MAKING; MEMORY DISORDER; MENTAL DISEASE; METABOLIC ACIDOSIS; MYOPIA; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NERVOUSNESS; NEUROLOGIC DISEASE; NYSTAGMUS; PAIN; PARESTHESIA; PATIENT CARE; PATIENT INFORMATION; PATIENT REFERRAL; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PHYSICIAN; PSYCHOMOTOR DISORDER; PSYCHOSIS; RASH; REVIEW; RHINITIS; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; STUPOR; TERATOGENICITY; THORAX PAIN; TIC; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREMOR; VIRUS INFECTION; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTICONVULSANTS; CHRONIC DISEASE; CONTINUITY OF PATIENT CARE; EMERGENCY MEDICINE; EMERGENCY SERVICE, HOSPITAL; EPILEPSY; FAMILY PRACTICE; HUMANS; INTERDISCIPLINARY COMMUNICATION; NEUROLOGY; PATIENT CARE TEAM; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION;

EID: 34547150154     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X199673     Document Type: Review

References (52)

1. Sheth RD. Adolescent issues in epilepsy. J Child Neurol 2002;17(Suppl 2):2S23-2S7
2. Bureau USC. 2006. Data finders: population clocks. Available from http://www.census.gov [last accessed 5 September 2006]
3. Shinnar S, Berg AT. Does antiepileptic drug therapy prevent the development of 'chronic' epilepsy? Epilepsia 1996;37:701-8
4. Nadkarni S, LaJoie J, Devinsky O. Current treatments of epilepsy. Neurology 2005;64:S2-S11
5. Kripalani S, LeFevre F, Phillips CO, et al. Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care. J Am Med Assoc 2007;297:831-41
6. Kyriacou DN, Handel D, Stein AC, et al. BRIEF REPORT: factors affecting outpatient follow-up compliance of emergency department patients. J Gen Intern Med 2005;20:938-42
7. Kanner AM, Balabanov AJ. The use of monotherapy in patients with epilepsy: an appraisal of the new antiepileptic drugs. Curr Neurol Neurosci Rep 2005;5:322-8
8. Bergey G. Initial treatment of epilepsy: special issues in treating the elderly. Neurology 2004;63:S40-S48
9. Sander JW. The use of antiepileptic drugs - principles and practice. Epilepsia 2004;45(Suppl 6):28-34
10. McCraig L, Nawar E. National hospital ambulatory medical care survey: 2004 emergency department summary. In: Advance data from vital and health statistics. Atlanta: Centers for Disease Control and Prevention, Health and Human Services; 2006. p. 1-30
11. Garnet WR. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy 2000;20:191S-199S
12. Carpay JA, Aldenkamp AP, van Donselaar CA. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 2005;14:198-206
13. Marks Jr WJ, Garcia PA. Management of seizures and epilepsy. Am Fam Physician 1998;57:1589-600, 603-4
14. Carter BL, Garnett WR, Pellock JM, et al. Effect of antacids on phenytoin bioavailability. Ther Drug Monit 1981;3:333-40
15. Donner EJ, Snead 3rd OC. New generation anticonvulsants for the treatment of epilepsy in children. NeuroRx 2006;3:170-80
16. Dickinson RG, Hooper WD, Patterson M, et al. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 1985;7:283-9
17. Fritz S, Lindner W, Roots I, et al. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987;241:615-22
18. Gates JR. Using new antiepileptic drugs as monotherapy. Curr Treat Options Neurol 2004;6:223-30
19. Engel Jr J, Starkman S. Overview of seizures. Emerg Med Clin North Am 1994;12:895-923
20. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products. General considerations. Available from http://www.fda.gov/cder/guidance/5356fnl.htm [last accessed 31 October 2006]
21. Benbadis SR. Practical management issues for idiopathic generalized epilepsies. Epilepsia 2005;46(Suppl 9):125-32
22. Bergey G. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005;46:161-8
23. Herman ST. Single unprovoked seizures. Curr Treat Options Neurol 2004;6:243-55
24. NICE. Quick reference guide. The epilepsies: diagnosis and management of the epilepsies in adults in primary and secondary care. Clinical Guideline 20, 2004, 73pp
25. Theodore W. Is epilepsy a progressive disease? Eur J Clin Res 2003;9:2
26. Nordli Jr DR. Special needs of the adolescent with epilepsy. Epilepsia 2001;42(Suppl 8):10-7
27. Roth HL, Drislane FW. Seizures. Neurol Clin 1998;16:257-84
28. French JA. Catamenial epilepsy: the elusive condition. Epilepsy Curr 2005;5:113-4
29. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003;61:S35-S42
30. Anon. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures. Ann Emerg Med 2004;43:605-25
31. Theodore WH, Porter RJ, Albert P, et al. The secondarily generalized tonic-clonic seizure: a videotape analysis. Neurology 1994;44:1403-7
32. Eisner RF, Turnbull TL, Howes DS, et al. Efficacy of a 'standard' seizure workup in the emergency department. Ann Emerg Med 1986;15:33-9
33. Sempere AP, Villaverde FJ, Martinez-Menendez B, et al. First seizure in adults: a prospective study from the emergency department. Acta Neurol Scand 1992;86:134-8
34. Kozer E, Scolnik D, Agamata WM, et al. Utility of antiepileptic drug monitoring in the pediatric emergency department. Ther Drug Monit 2003;25:17-21
35. Krumholz A, Grufferman S, Orr ST, et al. Seizures and seizure care in an emergency department. Epilepsia 1989;30:175-81
36. Karceski S, Morrell M, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005;7:S1-S64
37. Bazil MK, Bazil CW. Recent advances in the pharmacotherapy of epilepsy. Clin Ther 1997;19:369-82 [discussion 7-8]
38. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1252-60
39. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004;3:618-21
40. Sheth RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004;63:S24-S940
41. LYRICA [product insert]. New York, NY: Pfizer Inc
42. European Medicines Agency. Committee for medicinal products for human use post-authorisation summary of positive opinion for Keppra Doc. Ref. EMEA/CHMP/455195/2006
43. TRILEPTAL [product insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp
44. TOPAMAX [product insert]. Titusville, NJ: Ortho-McNeil Neurologies, Inc
45. NEURONTIN [product insert]. New York, NY: Pfizer Inc
46. LAMICTAL [product insert]. Research Triangle Park, NC: GlaxoSmithKline
47. GABITRIL [product insert]. West Chester, PA: Cephalon, Inc
48. FELBATOL [product insert]. Somerset, NJ: MedPoint Pharmaceuticals
49. DEPACON [product insert]. North Chicago, Illinois: Abbott Laboratories
50. CEREBYX [product insert]. Teaneck, NJ: Eisai Inc
51. KEPPRA [product insert], Smyrna, Georgia: UCB, Inc
52. ZONEGRAN [product insert]. Teaneck, NJ: Eisai Inc